Silo Pharma, Inc. Common Stock
SILO US82711P2011
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
Person | Price | Shares | Total | Published | Completed |
---|---|---|---|---|---|
Weisblum Eric CEO |
0.43 USD |
10,000 Bought |
4,329 USD |
27/05/2025 | 27/05/2025 |
Weisblum Eric CEO |
0.43 USD |
10,000 Bought |
4,329 USD |
27/05/2025 | 27/05/2025 |
Weisblum Eric CEO |
1.11 USD |
4,438 Bought |
4,926 USD |
11/06/2024 | 12/06/2024 |
Weisblum Eric CEO |
1.08 USD |
562 Bought |
607 USD |
11/06/2024 | 11/06/2024 |
Weisblum Eric CEO |
2.03 USD |
400 Bought |
812 USD |
04/04/2024 | 05/04/2024 |
Weisblum Eric CEO |
1.96 USD |
600 Bought |
1,176 USD |
04/04/2024 | 04/04/2024 |
Weisblum Eric CEO |
1.91 USD |
1,100 Bought |
2,101 USD |
28/03/2024 | 01/04/2024 |
Weisblum Eric CEO |
1.91 USD |
1,100 Bought |
2,101 USD |
28/03/2024 | 01/04/2024 |
Weisblum Eric CEO |
1.94 USD |
3,408 Bought |
6,612 USD |
28/03/2024 | 28/03/2024 |
Weisblum Eric CEO |
1.94 USD |
3,408 Bought |
6,612 USD |
28/03/2024 | 28/03/2024 |